Published in AIDS Weekly, July 15th, 2002
"Treatment of patients with human immunodeficiency virus (HIV) protease inhibitors such as ritonavir can result in increases in CD4+ T-cell counts that are independent of a reduction in HIV-1 viral load," according to Shibani Pati and colleagues working at the University of Maryland and Morgan State University in Baltimore.
Ritonavir has significant anticancer effects unrelated to its HIV-inhibiting abilities, the researchers found.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.